Could early blood thinner save more heart attack patients?

NCT ID NCT07361783

Disease control Sponsor: Chen Jing Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at giving a blood thinner called heparin to heart attack patients as soon as they see a doctor, rather than waiting until they are in the procedure room. About 6,294 participants will be randomly assigned to early or standard timing. The goal is to see if early treatment reduces death, another heart attack, or stroke within 30 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: unfractionated heparin (a blood thinner)
What this could lead to: If it works, this could show that giving heparin earlier during a heart attack improves survival and reduces complications.
What could go wrong: This is a large trial, but it tests a timing change for an existing drug, not a new treatment. The benefit may be small, and there is a risk of bleeding from the blood thinner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 6,294 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years old; 2. STEMI within 12 hours of onset Newly developed adjacent two or more leads with ST segment elevation of ≥1mm (lead V2-V3 elevation of ≥2mm). Newly developed left bundle branch block (LBBB). In the right bundle-branch block (RBBB), the ST segment of leads V1-V3 is elevated or Q waves occur. 3. Primary PCI was planned if the time from first medical contact to balloon dilatation was expected to be less than 120 minutes. Exclusion Criteria: 1. Thrombolytic therapy recipients; 2. Currently taking oral anticoagulant drugs or having been treated with heparin, low molecular weight heparin, suldaparinol sodium, bivalirudin or IIb/IIIa receptor antagonists within 48 hours before randomization; 3. Patients undergoing cardiopulmonary resuscitation; 4. Patients with cardiogenic shock; 5. Combined mechanical complications (rupture of the free wall of the heart, perforation of the ventricular septum, insufficiency or rupture of the papillary muscle leading to severe mitral regurgitation); 6. History of intracranial parenchymal aneurysm, intracranial arteriovenous malformation, intracranial hemorrhage, ischemic stroke or transient ischemic attack within the last 6 months, and active hemorrhage within the last 2 weeks; 7. Major surgery within one month; 8. Previous history of CABG; 9. Patients with a history of heparin-induced thrombocytopenia or those known to be allergic to anticoagulant or antiplatelet drugs; 10. Combined with other serious diseases and life expectancy less than 12 months; 11. Pregnant or lactating women; 12. Currently participating in clinical research on other drugs or devices; 13. Refuse to sign the informed consent form; 14. The researcher judged that it was not suitable to participate in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary pci are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary pci ST-elevation myocardial infarction (stemi)

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Could early blood thinner save more heart attack patients?

What the study statuses mean